O4-3 An update analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody

Ramucirumab (RAM) plus FOLFIRI has been considered as a standard of care 2nd-line treatment for RAS wild-type metastatic colorectal cancer (mCRC) after combination chemotherapy with oxaliplatin and anti-EGFR antibody. However, there have been few studies which prospectively evaluated the efficacy and safety of FOLFIRI plus anti-VEGF inhibitor after anti-EGFR antibody containing regimen. We therefore conducted the JACCRO CC-16 trial which investigated the clinical outcomes of 2nd-line RAM plus FOLFIRI in patients with RAS wild-type mCRC previously treated with anti-EGFR antibody containing regimen and had reported the positive data with 6-month progression free survival (PFS) rate of 58.2% at ASCO-GI 2022.